# A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

> **NCT04073615** · PHASE1 · TERMINATED · sponsor: **Elevar Therapeutics** · enrollment: 29 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Rivoceranib
- **DRUG:** Trifluridine/Tipiracil

## Key facts

- **NCT ID:** NCT04073615
- **Lead sponsor:** Elevar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-18
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Phase 2 portion of the study was not performed due to redirection of the rivoceranib development plan by the Sponsor.
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04073615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04073615, "A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04073615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*